(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 14.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Karyopharm Therapeutics's revenue in 2025 is $145,237,000.On average, 4 Wall Street analysts forecast KPTI's revenue for 2025 to be $1,264,858,674, with the lowest KPTI revenue forecast at $1,214,766,595, and the highest KPTI revenue forecast at $1,304,481,240. On average, 4 Wall Street analysts forecast KPTI's revenue for 2026 to be $1,468,147,348, with the lowest KPTI revenue forecast at $1,304,481,240, and the highest KPTI revenue forecast at $1,587,595,749.
In 2027, KPTI is forecast to generate $1,891,708,198 in revenue, with the lowest revenue forecast at $1,727,890,602 and the highest revenue forecast at $2,055,525,794.